Vanguard realigns reporting; holds 0 shares of STAAR Surgical (STAA)
Rhea-AI Filing Summary
STAAR Surgical Co filing: an amended Schedule 13G/A from The Vanguard Group reports 0 shares beneficially owned and 0% of common stock. The filing states Vanguard completed an internal realignment on January 12, 2026 and will report certain subsidiaries separately in reliance on SEC Release No. 34-39538.
The filing lists Vanguard's address and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does The Vanguard Group report for STAA in this Schedule 13G/A?
The Vanguard Group reports 0 shares beneficially owned of STAAR Surgical Co common stock, representing 0% of the class. The filing reflects an internal realignment and disaggregation of certain subsidiaries.
Why did Vanguard change its reporting for STAA on January 12, 2026?
Vanguard underwent an internal realignment and, per SEC Release No. 34-39538, certain subsidiaries will report beneficial ownership separately. Vanguard states those entities pursue the same investment strategies as before the realignment.
Who signed the Schedule 13G/A amendment for STAA?
Ashley Grim, Head of Global Fund Administration at The Vanguard Group, signed the amendment. The signature block shows the filing date as 03/27/2026.
Does the filing identify any third party with rights to dividends or sale proceeds for STAA?
The filing states The Vanguard Group, including registered investment companies and managed accounts, have the right to receive or direct dividends or sale proceeds, and no other person's interest exceeds 5% of the class.
What address is listed for STAAR Surgical Co in the filing?
The issuer's principal executive offices are listed as 25651 Atlantic Ocean Dr, Lake Forest, CA, 92630, per the filing's Item 1 disclosure.